Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.
about
Vaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy childrenVaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy childrenVaccines for preventing influenza in healthy adultsAn improved reverse genetics system for influenza A virus generation and its implications for vaccine productionConfronting potential influenza A (H5N1) pandemic with better vaccinesPreclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza VaccinesCell culture-based influenza vaccines: A necessary and indispensable investment for the futureNeedle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine productionGrowth determinants for H5N1 influenza vaccine seed viruses in MDCK cellsDesigning vaccines for pandemic influenza.Continuous cell lines as a production system for influenza vaccines.Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.Caveolin-1 influences human influenza A virus (H1N1) multiplication in cell culture.Development and strategies of cell-culture technology for influenza vaccine.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusionNew technologies for influenza vaccines.Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy.Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant virusesHigh yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice.A replication-incompetent PB2-knockout influenza A virus vaccine vector.Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patchThe future of cell culture-based influenza vaccine production.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Strategies for preventing influenza: future perspectives in influenza vaccine technology.A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 influenza A Virus in Cells.Cell culture-derived flu vaccine: Present and future.A Functional Food Mixture "Protector" Reinforces the Protective Immune Parameters against Viral Flu Infection in Mice.Vaccines against epidemic and pandemic influenza
P2860
Q24197955-E12B92C4-3420-4A11-9769-A2438C2E58CFQ24201525-DC3E4BB6-24F7-40F9-9552-D96C7DC51784Q24234114-88B00F66-8809-428A-8E11-2A0E1C76300DQ24243174-4522347E-6E9D-48F1-A98E-E5586CF1E9F4Q24245429-01C05E0D-79D7-44F4-A793-136CBEFA6958Q24537680-338E8080-2877-49F8-BB28-FA9D589022E9Q24601560-BED3E39E-8F02-45B5-BD4D-69CF0B8F1ADFQ27478355-9583755D-B0CB-4C80-A3F7-DAF1B61CB21CQ28084739-A4CDA4E8-36F5-4B47-8BC9-DBC5BFB355B5Q30361581-830848D9-37C3-42B3-AD14-8811386E4061Q30366174-A24D8918-1428-4DF5-AF79-A9CABC3CACA7Q30371848-8323BC9A-C13B-4260-BFEF-2B542EF30198Q30380889-44DA1AFF-39C1-4CA1-A2EB-793AA2D51FD8Q30382947-3DDED400-6D52-421D-A572-953264C69D39Q30389582-D85AD1CE-F23D-4C23-AF6F-74155C901D95Q30389699-01A02C53-944E-49BD-AFD3-DA4B5A37DC8EQ30396047-6309607E-37DA-4316-95CD-6EF7D83E89F8Q30407424-534EA663-00DF-42DA-998E-366F32BE6EABQ30409570-777F8AC6-3CAC-4F4D-A6D9-E66BDDE9C8E2Q30411859-28945024-F5D2-4199-9D07-32A917BED165Q30419591-BADD9B81-1868-443F-B727-85A92CC1D5D3Q33646793-26E998DD-39C9-4A36-9D7A-648316909604Q34141955-3187304D-1C78-4169-8EEB-26985F668423Q34652542-45E27EB3-221E-43F0-8AF3-31729EF9EF00Q34976150-7769326D-A3A3-4D66-9C42-603FFA7F30BFQ34984192-9530A79B-47E9-4069-87EA-F093169B076CQ35123457-0EB64353-F8DE-4BC6-BA09-0E1A3777D4E9Q35868034-F8EDF1EA-879B-4BB3-A27A-31E6B4755C7FQ36911322-0CC99FEC-328F-469F-958A-46BD82053239Q37087659-6A590B43-F449-4395-980D-A6EBF34D29C7Q37919896-8D2B4EA5-D2EA-4246-9E67-CC2EAB53E636Q38045920-E8FF0185-EFC9-442D-B16B-835E6FAC7954Q44902406-B37C1D3A-77BA-4B1B-A2D6-9143AD61EBB0Q45325112-CFC96445-99D5-4A8D-9053-E9C6FD83AD74Q52315669-7CB6A1C8-AD73-4090-8F99-81C609FB50C3Q55453056-2B0FE35D-BC77-4BCE-BD53-BCFA911ADD64Q56550815-3F555123-5989-44B3-85E7-BE8DAD3618A8
P2860
Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Safety and immunogenicity of a ...... adults, seniors, and children.
@en
type
label
Safety and immunogenicity of a ...... adults, seniors, and children.
@en
prefLabel
Safety and immunogenicity of a ...... adults, seniors, and children.
@en
P2093
P1433
P1476
Safety and immunogenicity of a ...... adults, seniors, and children.
@en
P2093
Bruce Smith
Elaine L Mills
John Treanor
Marc Germain
Pierre Trépanier
Richard Gauthier
Taoufik Mabrouk
Thomas Hassell
P304
P356
10.1016/S0264-410X(01)00428-5
P407
P577
2002-01-01T00:00:00Z